Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;84(6):463-468.
doi: 10.1111/ahg.12396. Epub 2020 Jun 2.

Carrier frequency of CFTR variants in the non-Caucasian populations by genome aggregation database (gnomAD)-based analysis

Affiliations

Carrier frequency of CFTR variants in the non-Caucasian populations by genome aggregation database (gnomAD)-based analysis

Stefania Nappo et al. Ann Hum Genet. 2020 Nov.

Abstract

The complexity in the molecular diagnosis of Cystic Fibrosis (CF) also depends on the variable prevalence/incidence of the disease associated with the wide CFTR allelic heterogeneity among different populations. In fact, CF incidence in Asian and African countries is underestimated and the few patients reported so far have rare or unique CFTR pathogenic variants. To obtain insights into CF variants profile and frequency, we used the large population sequencing data in the Genome Aggregation Database (gnomAD). We selected 207 CF-causing/varying clinical consequence variants from CFTR2 database and additional 15 variants submitted to the ClinVar database. Only 14 of these variants were found in the East-Asian population, while for South-Asian and African populations we identified 43 and 52 variants, respectively, confirming the peculiarity of the CFTR allelic spectrum with only few population-specific variants. These data could be used to optimize CFTR carrier screening in non-Caucasian subjects, choosing between the full gene sequencing and cost and time-effective targeted panels.

Keywords: CFTR; cystic fibrosis; gnomAD; non-Caucasian populations.

PubMed Disclaimer

References

REFERENCES

    1. American College of Obstetricians and Gynecologists Committee on Genetics. (2011). ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstetrics and gynecology, 117, 1028-1031. https://doi.org/10.1097/AOG.0b013e31821922c2
    1. Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002). Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening. Human Mutation, 19, 575-606. https://doi.org/10.1002/humu.10041
    1. Committee on Genetics (2017). Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstetrics and Gynecology, 129(3), e41-e55. https://doi.org/10.1097/AOG.0000000000001952
    1. D'Apice, M. R., Gambardella, S., Bengala, M., Russo, S., Nardone, A. M., Lucidi, V., … Novelli, G. (2004). Molecular analysis using DHPLC of cystic fibrosis: Increase of the mutation detection rate among the affected population in Central Italy. BMC Medical Genetics, 5, 8. https://doi.org/10.1186/1471-2350-5-8
    1. Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., … Sosnay, P. R. (2017). Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. The Journal of Pediatrics, 181S, S4-S15.e1. https://doi.org/10.1016/j.jpeds.2016.09.064

Substances

LinkOut - more resources